Li Y, Liang X, Li H, Chen X, et al. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer 2022 Sep 16. doi: 10.1002/cncr.34457.
PMID: 36111952